Aspirin for Preventing the Recurrence of Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: About 20% of patients with unprovoked venous thromboembolism have a recurrence within 2 years after the withdrawal of oral anticoagulant therapy. Extending anticoagulation prevents recurrences but is associated with increased bleeding. The benefit of aspirin for the prevention of recurrent venous thromboembolism is unknown. METHODS: In this multicenter, investigator-initiated, double-blind study, patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment were randomly assigned to aspirin, 100 mg daily, or placebo for 2 years, with the option of extending the study treatment. The primary efficacy outcome was recurrence of venous thromboembolism, and major bleeding was the primary safety outcome. RESULTS: Venous thromboembolism recurred in 28 of the 205 patients who received aspirin and in 43 of the 197 patients who received placebo (6.6% vs. 11.2% per year; hazard ratio, 0.58; 95% confidence interval [CI], 0.36 to 0.93) (median study period, 24.6 months). During a median treatment period of 23.9 months, 23 patients taking aspirin and 39 taking placebo had a recurrence (5.9% vs. 11.0% per year; hazard ratio, 0.55; 95% CI, 0.33 to 0.92). One patient in each treatment group had a major bleeding episode. Adverse events were similar in the two groups. CONCLUSIONS: Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding. (Funded by the University of Perugia and others; WARFASA ClinicalTrials.gov number, NCT00222677.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The WARFASA 309 and ASPIRE 318 trials compared aspirin, 100 mg daily, with placebo for secondary prevention of recurrent VTE for patients with an initial unprovoked event, and the pooled results of the 2 trials showed a decrease in recurrent VTE, as well as major vascular events, without an increased risk for clinically relevant bleeding. 309,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [309]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Consequently, several studies have investigated the role of aspirin for the secondary prevention of VTE. 309,314,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [309]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citation(2000) · The Lancet · doi:10.1016/s0140-6736(00)02110-3 · Cited by 1,076
Kearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
del Conde, I., Shrimpton, C. N., Thiagarajan, P., & López, J. A. (2005) · Blood · doi:10.1182/blood-2004-03-1095 · Cited by 1,029
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Linkins, L.-A., Choi, P. T., & Douketis, J. D. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-11-200312020-00007 · Cited by 764
Research works printed but not linked: 2
- Schulman S, 2011, J Thromb Haemost, 9, 731
- Schulman S, 2011, J Thromb Haemost, 9, 22
Cited by
Items 601–630 of 630
Becattini, C., Giustozzi, M., & Agnelli, G. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_162-1
Self-citationThe Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism
Prandoni, P. (2016) · Advances in experimental medicine and biology · doi:10.1007/13780_2016_29
Self-citationBecattini, C., Giustozzi, M., & Agnelli, G. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_162
Self-citationAspirin for venous thromboembolism
Stein, P. D. (2016) · Wiley eBooks · doi:10.1002/9781119039112.ch108
4 Clinical applications of aspirin
Schrör, K. (2022) · De Gruyter eBooks · doi:10.1515/9783110746419-004
Predicting Thromboembolism in Hospitalized Patients with Ventricular Thrombus
Yang, Q., Quan, X., Lang, X., & Liang, Y. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2312390
Wu, S., Hu, C., Wu, X., Zhou, X., & Huang, L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.27.522044
Ertürk, E., Ocak, K., Uyan, U., Çoner, A., Kocabaş, U., Kış, M., Başkurt, A. A., Oray, D., Sayın, B. Y., Mammadov, G., et al. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2688
Udombhornprabha, A. (2018) · Chula Digiverse · doi:10.58837/chula.the.2018.461 · Cited by 1
An overview in acquired hemophilia: A rare but complicated disease
Pasca, S. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231009sp
Aspirine et prévention de la récidive de la maladie veineuse thromboembolique
Salah, R. B., Derbel, A., Chabchoub, I., Frikha, F., Marzouk, S., & Bahloul, Z. (2024) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2024.101761
The Link between Arterial Atherosclerotic Disease and Venous Thromboembolic Disease
Poredoš, P., Poredoš, P., & Jezovnik, M. K. (2025) · Current Vascular Pharmacology · doi:10.2174/0115701611345232250212042958
The Effects of Statin Therapy on Mean Platelet Volume in Patients with Cardiovascular Diseases
Abdulrazzaq, A. A., Hani, R., & Saleh, A. R. (2025) · Stallion Journal for Multidisciplinary Associated Research Studies · doi:10.55544/sjmars.3.6.6
Platelets in Venous Thromboembolism
Riedl, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96352-0_13
Risks and Benefits of Nonsteroidal Anti-inflammatory Drugs in the Hemostatic System
Cignarella, A., Campello, E., Ramaschi, G. E., Simion, C., & Simioni, P. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2725-6989 · Cited by 3
Gebelik ve Hematolojik Yönleri
Ayyıldız, O., & Bozan, M. A. (2025) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2906
Orsi, L. D. A. F. (2020) · Leiden Repository (Leiden University)
Antiplatelet Therapy for Venous Thromboembolism
Poénou, G., & Heestermans, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_13
Involvement of platelets in inflammation and cancer
Mezouar, S. (2015) · theses.fr (ABES) · doi:10.70675/3209f579z7718z497fzbe5dzd52f700a4270
Microparticles in colorectal and pancreatic cancers
Mège, D. (2016) · theses.fr (ABES) · doi:10.70675/53ccc88ez4c57z4521zabb5z8a40f9335ca7
Pathophysiology of cardiovascular events in Bcr/Abl-negative myeloproliferative neoplasms
Poisson, J. (2018) · theses.fr (ABES) · doi:10.70675/d71df373z8cc7z41c1z9896zab996bc5b48e
Mahmoud, A. A., & Kouides, P. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-13858-3_46
Effects of cathelicidin on coagulation and venous thromboembolism
Zhang, Q. (2023) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.31973
The 2026 Multisociety Acute Pulmonary Embolism Guidelines: An Expert Perspective
Elmadhoun, O., Balanescu, D. V., Seelhammer, T. G., Alwatari, Y. A., BUDA, K. G., Ortoleva, J. P., Ahmad, S. R., Chaudhary, S., Ramanujan, K. S., Guru, P. K., et al. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.06.003
Enhancing venous thromboembolism risk prediction after immunotherapy for lung cancer
Wang, S., Wen, S., Zhao, M., Li, W., Yang, M., Chen, C., & Xu, X. (2026) · iScience · doi:10.1016/j.isci.2026.116890
Research on Simplified Design of Interface Interaction Process Based on TRIZ and Generative AI
Li, M., Liu, S., Wu, B., Zhao, X., & Ning, Z. (2026) · International Journal of Human-Computer Interaction · doi:10.1080/10447318.2026.2705084
Antiplatelet therapy in pulmonary embolism: Mechanisms and evidence
Kalamara, T.-V., Dodos, K., & Georgakopoulou, V. (2026) · World Journal of Translational Medicine · doi:10.5528/wjtm.121879
Contemporary anticoagulation management in pulmonary embolism
Hammerschlag, G., Yo, S., Lawton, E., & Dunn, A. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109854
Meng, S., Yu, S., Zhu, X., Zhou, S., Zhu, S., Yu, Y., Xie, Y., Huang, Z., Xiang, M., & Ma, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-77293-z
Xie, S., Xu, W., & Li, J. (2026) · Phlebology The Journal of Venous Disease · doi:10.1177/02683555261503887
Metadata
- Authors
- Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., Grandone, E., & Prandoni, P.
- Affiliations
- University of Perugia (IT)
- Ente Ospedaliero Ospedali Galliera (IT)
- Medical University of Vienna (AT)
- Ospedale per gli Infermi (IT)
- Santa Maria Nuova Hospital (IT)
- Ospedale Valduce (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- University of Insubria (IT)
- Casa Sollievo della Sofferenza (IT)
- University of Padua (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-05-24
- Volume
- 366
- Issue
- 21
- Pages
- 1959-1967
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1975990989
- Cited by
- 620
- References
- 37
- Citations by year
- 2026: 10 · 2025: 27 · 2024: 19 · 2023: 11 · 2022: 23 · 2021: 39 · 2020: 40 · 2019: 34 · 2018: 45 · 2017: 53 · 2016: 52 · 2015: 75 · 2014: 69 · 2013: 90 · 2012: 33
- FWCI
- 57.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Bayer HealthCare
- Università degli Studi di Perugia
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- aspirin, venous thromboembolism, recurrence prevention, unprovoked venous thromboembolism, major bleeding, secondary prevention, anticoagulation
- MeSH terms
- Aged, Anticoagulants, Aspirin, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Pulmonary Embolism, Vitamin K, Venous Thrombosis, Venous Thromboembolism, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.